Cambridge Healthtech Institute’s 10th Annual
Clinical and Translational Biomarkers
Precision Medicine, Liquid Biopsy, and Clinical Trials
June 2-4, 2020
The promise of precision medicine has been driven by the need to accurately predict patient response to therapy while ensuring drug efficacy and safety. Reducing costs and the time required for drug development is also a driving force in the use of biomarkers.
Cambridge Healthtech Institute’s 10th annual Clinical and Translational Biomarkers meeting will cover novel biomarker discovery, clinical and analytical biomarker validation, and the role of biomarkers in clinical decision making.
Precision Medicine Initiatives at the National Cancer Institute
Tracy G. Lively, PhD, Chief, Diagnostics Evaluation Branch, Deputy Associate Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute
Accelerating Oncology Drug Development by Patient Stratification
Hua C. Gong, MD, PhD, Senior Director, Head of Genomics Biomarker Development, Navigate Biopharma, a Novartis Company
Patient Selection Biomarkers for Neurodegenerative Diseases
Michael Baratta, PhD, Scientific Director, Clinical Biomarker Development Innovation, Takeda
Liquid Biopsies Enabling Precision Medicine
Jonathan Beer, Director, FPM Lead of Disruptive Technologies, Novartis Precision Medicine
Translational Biomarkers: From Discovery to the Clinic
Katherine Call, PhD, Senior Director, Head, Proteogenomics, Sanofi Translational Sciences
Personalized Serial Detection of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients with Pediatric Cancers
Rachel Nga Wan Tam, PhD, Senior Scientific Researcher, Oncology Biomarker Development, Genentech
Evaluation of NGS Assay Sensitivities in Liquid Biopsies for MRD
Amelia Raymond, Scientist, Translational Medicine, AstraZeneca
Liquid Biopsy for Brain Tumors
Brian V. Nahed, MD, MSc, Associate Professor, Neurosurgery, Harvard Medical School; Associate Director, Neurosurgery Residency Program, Massachusetts General Hospital
Overview of Genomic Biomarkers in Clinical Trials
Chetan Deshpande, Clinical Biomarker Assay Lead, Pfizer
Predictive Molecular Marker for C. Difficile Infection Recurrence
Xuemei Zhao, PhD, Senior Principal Scientist, Merck
High Resolution, High Throughput Single Vesicle Analysis
John Nolan, PhD, Professor, The Scintillon Institute